Attila Bérces

Attila Bérces has a diverse and extensive work experience in various industries. Attila started their career in 1990 as a PhD student at the University of Calgary, focusing on density functional theory. From 1995 to 2000, they worked as a Research Associate at the Steacie Institute for Molecular Sciences, where they developed computational algorithms and contributed to various biology programs.

In 2000, Bérces joined Novartis Institute for Biomedical Research as the Head of Laboratory for Computational Chemistry. During their time there, they provided computational chemistry support to drug discovery programs and received the "Bright Idea" corporate-level innovation award.

After their tenure at Novartis, Bérces worked at AstraZeneca R&D as the Associate Director Medicinal Chemistry and Head of Computational Chemistry. In this leadership role, they managed the growth of the Computational Chemistry section and served on the management team of a department consisting of over 200 scientists.

In 2005, Bérces founded Chemistry Logic, a company aimed at bringing the benefits of field programmable gate arrays to drug discovery. The company received government funding and developed scientific algorithms with groundbreaking performance.

From 2007 to 2013, Bérces worked as a Senior Consultant at Semmelweis Innovations, where they helped university inventors and innovators commercialize their technology and implemented educational programs.

In 2009, Bérces founded Omixon, a company focused on developing software tools for clinical and diagnostic labs to adopt next generation sequencing. Attila served as the CEO until 2013 and later became the Chairman and Founder of Omixon. Currently, as the CEO and Founder, Bérces is leading Omixon's introduction of new products, including the development and commercial introduction of the AzureSeq CE IVD coronavirus detection kit.

Throughout their career, Bérces has demonstrated their expertise in computational chemistry, innovation, and entrepreneurial endeavors, making valuable contributions to the fields of molecular sciences, drug discovery, and next generation sequencing.

Attila Bérces has a strong educational background in chemistry. Attila completed their undergraduate studies at Eötvös Loránd University from 1985 to 1990, where they earned their MSc degree in Chemistry. Attila then pursued further studies at the University of Calgary from 1990 to 1995, obtaining their Ph.D. in Chemistry.